Blueprint Medicines price target raised to $130 from $120 at Stifel

Stifel raised the firm’s price target on Blueprint Medicines to $130 from $120 and keeps a Buy rating on the shares. The company’s mast cell disease webinar “offered no new updates” for its wild-type KIT inhibitor BLU-808, but it did provide “a successful case for value attribution for this asset that remains largely outside of models,” the analyst tells investors. BLU-808 first healthy volunteer safety and biomarker data can significantly de-risk the odd of success for urticaria patient cohorts, the analyst added.